Hassan Yousefi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11527805/publications.pdf

Version: 2024-02-01

34 papers	1,537 citations	516215 16 h-index	476904 29 g-index
35 all docs	35 docs citations	35 times ranked	1964 citing authors

#	Article	IF	Citations
1	Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy. Molecular Cancer, 2022, 21, 15.	7.9	38
2	Nischarin Deletion Reduces Oxidative Metabolism and Overall ATP: A Study Using a Novel NISCHÎ”5-6 Knockout Mouse Model. International Journal of Molecular Sciences, 2022, 23, 1374.	1.8	2
3	Blockade of Nuclear Factor-Îšb (NF-Îšb) Pathway Using Bay 11-7082 Enhances Arsenic Trioxide-Induced Antiproliferative Activity in U87 Glioblastoma Cells. Reports of Biochemistry and Molecular Biology, 2022, 10, 602-613.	0.5	0
4	NR4A Family Genes: A Review of Comprehensive Prognostic and Gene Expression Profile Analysis in Breast Cancer. Frontiers in Oncology, 2022, 12, 777824.	1.3	6
5	A novel NSC small molecule inhibitor inhibits proliferation of tripleâ€negative breast cancer cells through metabolic reprograming. FASEB Journal, 2022, 36, .	0.2	0
6	Abstract 1477: Circulating miR-125a-3p and miR-451a may be liquid biopsy biomarkers for the diagnosis of breast cancer. Cancer Research, 2022, 82, 1477-1477.	0.4	0
7	Docosahexaenoic acid reverses the promoting effects of breast tumor cell-derived exosomes on endothelial cell migration and angiogenesis. Life Sciences, 2021, 264, 118719.	2.0	25
8	Effects of different autophagy inhibitors on sensitizing <scp>KG</scp>â€1 and <scp>HL</scp>â€60 leukemia cells to chemotherapy. IUBMB Life, 2021, 73, 130-145.	1.5	8
9	Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance. Oncogene, 2021, 40, 1043-1063.	2.6	61
10	The oncogenic and tumor suppressive roles of RNAâ€binding proteins in human cancers. Journal of Cellular Physiology, 2021, 236, 6200-6224.	2.0	17
11	Opposite trends of GAS6 and GAS6-AS expressions in breast cancer tissues. Experimental and Molecular Pathology, 2021, 118, 104600.	0.9	3
12	Immune and metabolic checkpoints blockade: Dual wielding against tumors. International Immunopharmacology, 2021, 94, 107461.	1.7	13
13	Role of SPDEF gene enhancer and promoter methylation in prostate cancer cell metastasis and therapeutic resistance. FASEB Journal, 2021, 35, .	0.2	1
14	Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer. Cancer Letters, 2021, 507, 112-123.	3.2	52
15	Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells. Life Sciences, 2021, 287, 120100.	2.0	5
16	Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance. Oncogene, 2020, 39, 953-974.	2.6	146
17	SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach. Biomedicine and Pharmacotherapy, 2020, 130, 110548.	2.5	29
18	DICER-AS1 lncRNA: A putative culprit in the pathogenesis of gastric cancer. Experimental and Molecular Pathology, 2020, 116, 104490.	0.9	6

#	Article	IF	Citations
19	Non-coding RNAs underlying chemoresistance in gastric cancer. Cellular Oncology (Dordrecht), 2020, 43, 961-988.	2.1	29
20	MTHFR gene polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis based on 16 studies. Clinical Rheumatology, 2020, 39, 2267-2279.	1.0	15
21	Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells. European Journal of Pharmacology, 2020, 882, 173298.	1.7	5
22	Vitamin D receptor (VDR) gene polymorphism and risk of rheumatoid arthritis (RA): systematic review and meta-analysis. Clinical Rheumatology, 2020, 39, 3555-3569.	1.0	24
23	Clinicopathological Significance of Long Non-Coding RNA GHET1 in Human Cancers: A Meta-Analysis. Current Pharmaceutical Biotechnology, 2020, 21, 1422-1432.	0.9	6
24	EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells. Iranian Biomedical Journal, 2020, 24, 365-373.	0.4	7
25	IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer. Tumori, 2019, 105, 84-91.	0.6	29
26	Generation of Induced Pluripotent Cancer Cells from Glioblastoma Multiform Cell Lines. Cellular Reprogramming, 2019, 21, 238-248.	0.5	3
27	Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells. European Journal of Pharmacology, 2019, 863, 172705.	1.7	15
28	The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. Cellular Oncology (Dordrecht), 2019, 42, 491-504.	2.1	18
29	Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Molecular Cancer, 2019, 18, 75.	7.9	853
30	Blockade of nuclear factor-ÎºB (NF-ÎºB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells. International Journal of Biochemistry and Cell Biology, 2018, 99, 1-9.	1.2	31
31	Homology Modeling and Epitope Prediction of NadA as a Potential Vaccine Candidate in. International Journal of Molecular and Cellular Medicine, 2018, 7, 53-68.	1.1	7
32	Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. Scientific Reports, 2017, 7, 45954.	1.6	29
33	Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. Scientific Reports, 2017, 7, 44075.	1.6	27
34	Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Scientific Reports, 2017, 7, 4204.	1.6	27